Perspective Therapeutics' (CATX) NET program to potentially treat neuroendocrine tumors may be advan

Profound Medical (PROF) delivered earnings and revenue surprises of +218.18% and -55.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Perspective Therapeutics Inc. (NYSE:CATX) is one of the best high-return penny stocks to buy right now. On February 2, Perspective Therapeutics Inc. (NYSE:CATX) priced an underwritten offering of 39.57 million shares at $3.78 per share. The company anticipates gross proceeds of $175 million from the offering. It plans to use the net proceeds from the […]